Skip to main content
OpenTrials

Clinical trial condition

Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Explore clinical trials studying Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma trial results

Completed

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931

Conditions
Carcinoma, Carcinoma, Squamous Cell, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, +13 more
Locations
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Providence St. John's Health Center Santa Monica, California, United States
  • University of Colorado Denver Aurora, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 24 locations
View Trial Details

Related conditions